Literature DB >> 11814419

Down regulation of COX-2 is involved in hyperbaric oxygen treatment in a rat transient focal cerebral ischemia model.

Wei Yin1, Ahmed E Badr, George Mychaskiw, John H Zhang.   

Abstract

The effect of hyperbaric oxygen (HBO) on cyclooxygenase-2 (COX-2) expression after transient focal ischemia was evaluated. A rat middle cerebral artery occlusion/reperfusion (MCAO) model was produced using the intraluminal filament method. After 2 h of occlusion, 24 h of reperfusion, brains were removed. Three atmospheres absolute HBO for 1 h was administered at 6 h after reperfusion. The infarct volume was evaluated by 2,3,7-triphenyltetrazolium chloride staining. COX-2 mRNA expression was measured by reverse transcription polymerase chain reaction, and COX-2 protein expression was analyzed by Western blot. The results showed that HBO applied at 6 h after reperfusion significantly reduces infarct area as compared with no-treatment group. HBO decreased COX-2 mRNA and protein levels, which were upregulated after ischemia/reperfusion. HBO had no direct effect on COX-2 protein expression in matched normal rats. We conclude that (1) early intervention with HBO within 6 h reduces infarction. (2) The neuroprotective effect of HBO might lead to an inhibition of COX-2 over-expression in cerebral cortex.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11814419     DOI: 10.1016/s0006-8993(01)03304-2

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  23 in total

1.  Delayed and multiple hyperbaric oxygen treatments expand therapeutic window in rat focal cerebral ischemic model.

Authors:  Dali Yin; John H Zhang
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

Review 2.  Hyperbaric oxygen therapy in acute ischemic stroke: a review.

Authors:  Zheng Ding; Wesley C Tong; Xiao-Xin Lu; Hui-Ping Peng
Journal:  Interv Neurol       Date:  2014-08

3.  Hyperbaric oxygen inhibits stimulus-induced proinflammatory cytokine synthesis by human blood-derived monocyte-macrophages.

Authors:  R M Benson; L M Minter; B A Osborne; E V Granowitz
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

4.  Protection against focal ischemic injury to the brain by trans-sodium crocetinate. Laboratory investigation.

Authors:  Hiroaki Manabe; David O Okonkwo; John L Gainer; Ryon H Clarke; Kevin S Lee
Journal:  J Neurosurg       Date:  2010-10       Impact factor: 5.115

5.  Hyperbaric oxygenation alleviates MCAO-induced brain injury and reduces hydroxyl radical formation and glutamate release.

Authors:  Zhong-jin Yang; Yan Xie; Geraldo M Bosco; Chung Chen; Enrico M Camporesi
Journal:  Eur J Appl Physiol       Date:  2009-10-23       Impact factor: 3.078

6.  A PCR microreactor machinery with passive micropump and battery-powered heater for thermo-cycled amplifications of clinical-level and multiplexed DNA targets.

Authors:  Bing Shi; Gengxian He; Wenming Wu
Journal:  Mikrochim Acta       Date:  2018-09-18       Impact factor: 5.833

Review 7.  A review on the neuroprotective effects of hyperbaric oxygen therapy.

Authors:  Fahimeh Ahmadi; Ali Reza Khalatbary
Journal:  Med Gas Res       Date:  2021 Apr-Jun

8.  Normobaric oxygen therapy in acute ischemic stroke: A pilot study in Indian patients.

Authors:  M V Padma; A Bhasin; R Bhatia; A Garg; M B Singh; M Tripathi; K Prasad
Journal:  Ann Indian Acad Neurol       Date:  2010-10       Impact factor: 1.383

9.  Long course hyperbaric oxygen stimulates neurogenesis and attenuates inflammation after ischemic stroke.

Authors:  Ying-Sheng Lee; Chung-Ching Chio; Ching-Ping Chang; Liang-Chao Wang; Po-Min Chiang; Kuo-Chi Niu; Kuen-Jer Tsai
Journal:  Mediators Inflamm       Date:  2013-02-21       Impact factor: 4.711

10.  Hyperbaric oxygen and hyperbaric air treatment result in comparable neuronal death reduction and improved behavioral outcome after transient forebrain ischemia in the gerbil.

Authors:  Michal Malek; Malgorzata Duszczyk; Marcin Zyszkowski; Apolonia Ziembowicz; Elzbieta Salinska
Journal:  Exp Brain Res       Date:  2012-10-02       Impact factor: 1.972

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.